KCM
AEGR

Kennedy Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Kennedy Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-139,880
Closed -$2.93M – 786
2014
Q4 		$2.93M Buy
+139,880
New +$3.52M 0.05% 511
2014
Q3 		– Sell
-10,405
Closed -$334K – 808
2014
Q2 		$334K Buy
10,405
+4,593
+79% +$171K 0.01% 719
2014
Q1 		$268K Buy
+5,812
New +$341K 0.01% 723

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kennedy Capital Management's AEGR Position: Q1 2015 in Review

Kennedy Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2015, closing a stake of 139,880 shares — an estimated $2.93M sold.

Kennedy Capital Management first reported a position in AEGR in Q1 2014 and held it in 3 quarters. The position peaked at $2.93M in Q4 2014. 99 funds tracked by Wall St. Rank hold AEGR as of Q1 2015.

  • Kennedy Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Kennedy Capital Management sold 139,880 Aegerion Pharmaceuticals shares in Q1 2015, an estimated $2.93M.
  • Kennedy Capital Management first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Kennedy Capital Management's Aegerion Pharmaceuticals position peaked at $2.93M in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2015.

Based on Kennedy Capital Management's 13F filing for Q1 2015, filed 7 May 2015.